Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Rubigen: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Rubigen - General Information

A drug formerly used as an antipsychotic but now used primarily in the treatment of various movement disorders including tardive dyskinesia. Rubigen blocks uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system. [PubChem]

 

Pharmacology of Rubigen

Not Available

 

Additional information about Rubigen

Rubigen Indication: For the symptomatical treatment of hyperkinetic movement disorder. Mechanism Of Action: Rubigen works mainly as a VMAT-inhibitor and as such promotes the early metabolic degradation of the neurotransmitter dopamine. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Tetrabenazine Synonyms: Tetra benazin; Tetrabenazina [inn-spanish]; Tetrabenazinum [inn-latin]; Tetrabenzaine; Tetrabenzine Drug Category: Adrenergic Uptake Inhibitors Drug Type: Small Molecule; Approved Other Brand Names containing Tetrabenazine: Nitoman; Regulin; Rubigen; Xenazine; Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: Not Available Dosage Forms of Rubigen: Tablet Oral Chemical IUPAC Name: 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydropyrido[2,1-a]isoquinolin-2-one Chemical Formula: C19H27NO3 Tetrabenazine on Wikipedia: https://en.wikipedia.org/wiki/Tetrabenazine Organisms Affected: Humans and other mammals